Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00921_DB01037_nanopub.RAnvhS1ha28S08KaB2vLfT3nEny_vPp-X9olb_-u57p8I#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00921_DB01037 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00921_DB01037 label "DDI between Buprenorphine and Selegiline - Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like selegiline. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects. [drugbank_resource:DB00921_DB01037]" assertion.
- drugbank_resource:DB00921_DB01037 identifier "drugbank_resource:DB00921_DB01037" assertion.
- drugbank_resource:DB00921_DB01037 title "DDI between Buprenorphine and Selegiline - Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like selegiline. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects." assertion.
- drugbank:DB01037 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00921_DB01037 assertion.
- drugbank:DB00921 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00921_DB01037 assertion.